

**LISTING OF THE CLAIMS**

1-40. (canceled).

41. (original) A method for detecting a virus that is not a plus-strand RNA virus in a sample, comprising:

- a) providing:
  - i) a sample;
  - ii) cells susceptible to said virus that is not a plus-strand RNA virus;
  - and
  - iii) at least one protease inhibitor;
- b) contacting said cells and said sample in the presence of said protease inhibitor to produce contacted cells, wherein replication of said virus that is not a plus-strand RNA virus in said contacted cells is not reduced relative to replication of said virus that is not a plus-strand RNA virus in cells not contacted with said protease inhibitor, and wherein replication of a plus-strand RNA virus in said cells contacted with said protease inhibitor is reduced relative to replication of said plus-strand RNA virus in cells not contacted with said protease inhibitor.

42. (original) The method of Claim 41, wherein said virus that is not a plus-strand RNA virus is chosen from influenza virus, parainfluenza virus, adenovirus, respiratory syncytial virus, and metapneumovirus.

43. (original) The method of Claim 42, wherein said influenza virus is chosen from influenza A, influenza B, and influenza C.

44. (original) The method of Claim 42, wherein said parainfluenza virus is chosen from parainfluenza 1, parainfluenza 2, parainfluenza 3, and parainfluenza 4.

45. (original) The method of Claim 42, wherein said adenovirus is chosen from adenovirus 2, adenovirus 3, adenovirus 4, adenovirus 5, adenovirus 7, adenovirus 9, adenovirus 12, adenovirus 17, and adenovirus 40.

46. (original) The method of Claim 41, wherein said plus-strand RNA virus is chosen from togavirus, flavivirus, coronavirus, and picornavirus.

47. (original) The method of Claim 46, wherein said coronavirus comprises SARS-coronavirus.

48-51. (canceled)

52. (previously presented) The method of Claim 41, wherein said protease inhibitor is contained in a composition comprising a cyclodextrin.

53. (previously presented) The method of Claim 52, wherein said cyclodextrin is Captisol.

54. (previously presented) The method of Claim 41, wherein said protease inhibitor is selected from Actinonin, Glycyrrhizin, and E64D.

55. (original) A method for inhibition of human coronavirus 229E replication comprising:  
i) providing a composition comprising the protease inhibitor E64D and Captisol; and ii) contacting a cell permissive for 229E replication with said composition under conditions suitable for inhibiting 229E replication in said cell.

56-67. (canceled)

68. (previously presented) The method of Claim 55, wherein said cell permissive for 229E replication is selected from the group consisting of a human embryonic kidney (HEK)-293 cell, a HEK-293T cell, a Huh-7 cell, a mink lung cell, a Mv1Lu cell, a primary rhesus monkey kidney (pRHK) cell and a primary cynomolgus monkey kidney (pCMK) cell.